Table 2.
Pt | Sex | Age | Diagnosis | FG | size (cm) | Tumor stage |
---|---|---|---|---|---|---|
01 | M | 34 | RCC CC | 2 | 6.5 | pT1b, Nx, Mx |
02 | M | 63 | ONCO | na | 4.0 | na |
03 | F | 43 | RCC SARC | 4 | 29.0 | pT2, N0, M0 |
04 | M | 53 | RCC CC | 3 | 10.0 | pT3a, Nx, Mx |
05 | M | 31 | CHROMO | 4 | 3.0 | pT1a, Nx, Mx |
06 | M | 67 | RCC CC | 4 | 7.5 Multiple masses | pT4, Nx, Mx |
07 | M | 80 | RCC CC | 3 | 8.0 | pT2, N0, Mx |
08 | M | 73 | AML | na | na | na |
09 | F | 59 | RCC CC | 1 | 8.3 | pT2, N0, Mx |
10 | F | 53 | RCC CC | 2 | 6.0 | pT1b, Nx, Mx |
11 | F | 83 | RCC CC | 3 | 3.7 | pT3a, Nx, Mx |
12 | M | 55 | RCC CC | 2 | 4.0 | pT3b, Nx, Mx |
13 | M | 67 | RCC CC | 2 | 3.5 | pT1a, Nx, Mx |
14 | M | 85 | CHROMO | 1 | 5.1 | pT3a, Nx, Mx |
15 | M | 65 | RCC Pap | 3 | 3.5 | pT3a, Nx, Mx |
16 | M | 55 | RCC CC | 3 | 10.0 | pT3a, N0, Mx |
17 | F | 65 | AML | na | 4.0 | na |
18 | M | 65 | RCC CC | 3 | 12.0 | pT3b, N0, Mx |
19 | F | 86 | RCC CC | 1 | 10.1 | pT2b, N0, Mx |
20 | F | 56 | RCC CC | 2 | 5.0 | pT1b, Nx, Mx |
21 | M | 71 | ONCO | na | 4.8 | na |
22 | M | 83 | RCC CC | 2 | 5.3 | pT1b, Nx, Mx |
23 | M | 75 | RCC CC | 2 | 5.5 | pT3b, Nx, Mx |
24 | M | 48 | ONCO | na | 6.2 | na |
FG, Fuhrman grade; RCC, renal cell cancer; CC, RCC clear cell; PAP, RCC papillary; CHROMO, RCC chromophobe; SARC, sarcomatoid; AML, angiomyolipoma; ONCO, oncocytoma.